Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)

Javier Bolaños-Meade, Ran Reshef, Raphael Fraser, Mingwei Fei, Sunil Abhyankar, Zaid Al-Kadhimi, Amin M. Alousi, Joseph H. Antin, Sally Arai, Kate Bickett, Yi Bin Chen, Lloyd E. Damon, Yvonne A. Efebera, Nancy L. Geller, Sergio A. Giralt, Parameswaran Hari, Shernan G. Holtan, Mary M. Horowitz, David A. Jacobsohn, Richard J. JonesJane L. Liesveld, Brent R. Logan, Margaret L. MacMillan, Marco Mielcarek, Pierre Noel, Joseph Pidala, David L. Porter, Iskra Pusic, Ronald Sobecks, Scott R. Solomon, Daniel J. Weisdorf, Juan Wu, Marcelo C. Pasquini, John Koreth

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)'. Together they form a unique fingerprint.

Medicine & Life Sciences